Search results
Results from the WOW.Com Content Network
[8] [9] Epoetin alfa is an erythropoiesis-stimulating agent. [8] It stimulates erythropoiesis (increasing red blood cell levels) and is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy. Epoetin alfa is developed by Amgen. [8] It is on the World Health Organization's List of Essential Medicines. [10]
epoetin beta: NeoRecormon, made by Hoffmann–La Roche; Recormon; Methoxy polyethylene glycol-epoetin beta (Mircera) by Roche [20] epoetin delta: Dynepo trademark name for an erythropoiesis stimulating protein, by Shire plc [21] epoetin omega: Epomax; epoetin zeta (biosimilar forms for epoetin alpha): Silapo (STADA Arzneimittel AG) [22]
n/a n/a Ensembl n/a n/a UniProt n a n/a RefSeq (mRNA) n/a n/a RefSeq (protein) n/a n/a Location (UCSC) n/a n/a PubMed search n/a n/a Wikidata View/Edit Human Erythropoietin (/ ɪ ˌ r ɪ θ r oʊ ˈ p ɔɪ. ɪ t ɪ n, - r ə -, - p ɔɪ ˈ ɛ t ɪ n, - ˈ iː t ɪ n / ; EPO), also known as erythropoetin, haematopoietin, or haemopoietin, is a glycoprotein cytokine secreted mainly by the kidneys ...
Under the trade name Mircera, Roche Pharmaceuticals received approval from the U.S. Food and Drug Administration (FDA) in January 2008 to market a continuous erythropoiesis receptor activator (methoxy polyethylene glycol-epoetin beta) for the treatment of anemia in patients with chronic kidney disease, including in those undergoing dialysis.
Epoetin beta , sold under the brand name Neorecormon among others, is a synthetic, recombinant [4] form of erythropoietin, a protein that promotes the production of red blood cells. It is an erythropoiesis-stimulating agent (ESA) that is used to treat anemia , commonly associated with chronic kidney failure and cancer chemotherapy .
Peginesatide [2] (INN/USAN, trade name Omontys, formerly Hematide), developed by Affymax and Takeda, is an erythropoietic agent, a functional analog of erythropoietin.. It was approved by the U.S. Food and Drug Administration for treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis.
After successful tests on patients undergoing dialysis, Epoetin alfa, marketed by Amgen under the trade name Epogen starting in 1989, became a financial success, generating a billion-dollar market for Amgen and other companies that had developed their own versions of erythropoietin, though Goldwasser would say that "the enormous clinical ...
Epoetin alfa; Epoetin beta; M. Methoxy polyethylene glycol-epoetin beta This page was last edited on 5 May 2019, at 10:21 (UTC). Text is ...